Show simple item record

dc.contributor.authorDane, Faysal
dc.date.accessioned2016-03-09T18:48:19Z
dc.date.available2016-03-09T18:48:19Z
dc.date.issued2015
dc.identifier.issn10104283
dc.identifier.urihttp://tinyurl.com/jnyrod2
dc.identifier.urihttp://hdl.handle.net/11424/4257
dc.description.abstractPatients with advanced non-small cell lung cancer (NSCLC) generally require second-line treatment although their prognosis is poor. In this multicenter study, we aimed to detect the characteristics related to patients and disease that can predict the response to second-line treatments in advanced NSCLC. Data of 904 patients who have progressed after receiving first-line platinum-based chemotherapy in 11 centers with the diagnosis of stage IIIB and IV NSCLC and who were evaluated for second-line treatment were retrospectively analyzed. The role of different factors in determining the benefit of second-line treatment was analyzed. Median age of patients was 57 years (range 19–86). Docetaxel was the most commonly used (20.9 %, n = 189) single agent, while gemcitabine–platinum was the most commonly used (6.7 %, n = 61) combination chemotherapy regimen in second-line setting. According to survival analysis, median progression-free survival after first-line treatment (PFS2) was 3.5 months (standard error (SE) 0.2; 95 % confidence interval (CI), 3.2–3.9), median overall survival (OS) was 6.7 months (SE 0.3; 95 % CI, 6.0–7.3). In multivariate analysis, independent factors affecting PFS2 were found to be hemoglobin (Hb) level over 12 g/dl and treatment-free interval (TFI) longer than 3 months (p = 0.006 and 0.003, respectively). Similarly, in OS analysis, Hb level over 12 g/dl and time elapsed after the first-line treatment that is longer than 3 months were found to be independent prognostic factors (p = 0.0001 and 0.045, respectively). In light of these findings, determining and using the parameters for which the treatment will be beneficial prior to second-line treatment can increase success rate. © 2015, International Society of Oncology and BioMarkers (ISOBM).en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s13277-015-3728-0en_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectHemoglobin level; Non-small cell lung cancer; Prognostic factors; Second-line treatment; Survivalen_US
dc.titleIs second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncologyen_US
dc.typearticleen_US
dc.contributor.authorIDTR172195en_US
dc.relation.journalTumor Biologyen_US
dc.contributor.departmentDepartment of Medical Oncology, Marmara University Faculty of Medicineen_US
dc.identifier.volume36en_US
dc.identifier.issue12en_US
dc.identifier.startpage9641en_US
dc.identifier.endpage9648en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record